Medicaid AMP Rule Implementation Delay Requested By PhRMA, BIO, GPhA
This article was originally published in The Pink Sheet Daily
Executive Summary
Groups send joint letter to CMS urging delay in average manufacturer price methodology.
You may also be interested in...
AMP-Based Drug Reimbursement Not Enticing Many States, Survey Shows
More state Medicaid directors say they will not consider AMPs to set rates for brand-name drugs in 2008.
AMP-Based Drug Reimbursement Not Enticing Many States, Survey Shows
More state Medicaid directors say they will not consider AMPs to set rates for brand-name drugs in 2008.
Pharmacy Groups File Suit To Stop New Medicaid Drug Payment System
Pharmacies could lose $8 billion over next five years if data used to set average manufacturer prices includes mail-order, clinic and physician sales, trade groups assert.